2100 Wharton Street
Suite 701
Pittsburgh, PA 15203
United States
412 586 5830
https://www.krystalbio.com
版塊: Healthcare
行業: Biotechnology
全職員工: 229
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Mr. Krish S. Krishnan M.B.A., M.S. | Founder, Chairman, President & CEO | 1.32M | 無 | 1965 |
Ms. Suma M. Krishnan | Founder, President of R&D and Director | 895.33k | 無 | 1965 |
Ms. Kathryn A. Romano | Executive VP & Chief Accounting Officer | 614.87k | 2.35M | 1982 |
Mr. John Thomas | General Counsel & Corporate Secretary | 無 | 無 | 無 |
Mr. John Karakkal | Vice President of North American Sales & Marketing | 無 | 無 | 無 |
Ms. Christine Wilson | Head of U.S. Sales and Marketing | 無 | 無 | 無 |
Dr. Stephane Paquette Ph.D. | Vice President of Corporate Development | 無 | 無 | 無 |
Mr. Josh Suskin | Director of Human Resources & Operations | 無 | 無 | 無 |
Mr. Laurent Goux | Senior VP & GM of Europe | 無 | 無 | 無 |
Mr. David Chien | Senior Vice President of Clinical Development | 無 | 無 | 無 |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
截至 2024年6月1日 止,Krystal Biotech, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中:3;董事會:9;股東權利:8;現金賠償:5。